Search Results
Search for other papers by Nicolai Preisler in
Google Scholar
PubMed
Search for other papers by Pascal Laforêt in
Google Scholar
PubMed
Search for other papers by Karen Lindhardt Madsen in
Google Scholar
PubMed
Search for other papers by Edith Husu in
Google Scholar
PubMed
Search for other papers by Christoffer Rasmus Vissing in
Google Scholar
PubMed
Search for other papers by Gitte Hedermann in
Google Scholar
PubMed
Search for other papers by Henrik Galbo in
Google Scholar
PubMed
Search for other papers by Christopher Lindberg in
Google Scholar
PubMed
Search for other papers by John Vissing in
Google Scholar
PubMed
Objective
Pompe disease (glycogenosis type II) is caused by lysosomal alpha-glucosidase deficiency, which leads to a block in intra-lysosomal glycogen breakdown. In spite of enzyme replacement therapy, Pompe disease continues to be a progressive metabolic myopathy. Considering the health benefits of exercise, it is important in Pompe disease to acquire more information about muscle substrate use during exercise.
Methods
Seven adults with Pompe disease were matched to a healthy control group (1:1). We determined (1) peak oxidative capacity (VO2peak) and (2) carbohydrate and fatty acid metabolism during submaximal exercise (33 W) for 1 h, using cycle-ergometer exercise, indirect calorimetry and stable isotopes.
Results
In the patients, VO2peak was less than half of average control values; mean difference −1659 mL/min (CI: −2450 to −867, P = 0.001). However, the respiratory exchange ratio increased to >1.0 and lactate levels rose 5-fold in the patients, indicating significant glycolytic flux. In line with this, during submaximal exercise, the rates of oxidation (ROX) of carbohydrates and palmitate were similar between patients and controls (mean difference 0.226 g/min (CI: 0.611 to −0.078, P = 0.318) and mean difference 0.016 µmol/kg/min (CI: 1.287 to −1.255, P = 0.710), respectively).
Conclusion
Reflecting muscle weakness and wasting, Pompe disease is associated with markedly reduced maximal exercise capacity. However, glycogenolysis is not impaired in exercise. Unlike in other metabolic myopathies, skeletal muscle substrate use during exercise is normal in Pompe disease rendering exercise less complicated for e.g. medical or recreational purposes.
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg, Denmark
Search for other papers by Jakob Høgild Langdahl in
Google Scholar
PubMed
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Anja Lisbeth Frederiksen in
Google Scholar
PubMed
Search for other papers by John Vissing in
Google Scholar
PubMed
Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark
Search for other papers by Morten Frost in
Google Scholar
PubMed
Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark
Search for other papers by Knud Bonnet Yderstræde in
Google Scholar
PubMed
Search for other papers by Per Heden Andersen in
Google Scholar
PubMed
Aim
This case–control study aimed to examine impairments in glucose metabolism in non-diabetic carriers of the mitochondrial mutation m.3243A>G by evaluating insulin secretion capacity and sensitivity.
Methods
Glucose metabolism was investigated in 23 non-diabetic m.3243A>G carriers and age-, sex- and BMI-matched healthy controls with an extended 4-h oral glucose tolerance test (OGTT). Insulin sensitivity index and acute insulin response were estimated on the basis of the OGTT. This was accompanied by examination of body composition by dual-energy X-ray absorptiometry (DXA), maximum aerobic capacity and a Recent Physical Activity Questionnaire (RPAQ).
Results
Fasting p-glucose, s-insulin and s-c-peptide levels did not differ between m.3243A>G carriers and controls. Insulin sensitivity index (BIGTT-S1) was significantly lower in the m.3243A>G carriers, but there was no difference in the acute insulin response between groups. P-lactate levels were higher in carriers throughout the OGTT. VO2max, but not BMI, waist and hip circumferences, lean and fat body mass%, MET or grip strength, was lower in mutation carriers. BIGTT-S1 remained lower in mutation carriers after adjustment for multiple confounding factors including VO2max in regression analyses.
Conclusions
Glucose metabolism in m.3243A>G carriers was characterized by reduced insulin sensitivity, which could represent the earliest phase in the pathogenesis of m.3243A>G-associated diabetes.
